CancerH-62 thwarts leukemia in the preclinical settingInvestigators from the Guizhou Medical University have recently published data on H-62, a novel letermovir derivative and DNMT/tubulin dual inhibitor for the potential treatment of leukemia; H-62 was evaluated in vitro and in vivo in models of leukemia.